Arcutis Biotherapeutics, Inc. Stock Research

Market Summary

USD7.30-0.51

Delayedas of 31 May 2023, 01:12 pm

-6.53%

ARQT Stock Price

ARQT RSI Chart

ARQT Valuation

Market Cap

479.2M

Price/Earnings (Trailing)

-1.46

Price/Sales (Trailing)

55.58

Price/Free Cashflow

-1.7

ARQT Price/Sales (Trailing)

ARQT Profitability

Operating Margin

79.54%

Return on Equity

-148.61%

Return on Assets

-69.32%

Free Cashflow Yield

-58.72%

ARQT Fundamentals

ARQT Revenue

Revenue (TTM)

8.6M

ARQT Earnings

Earnings (TTM)

-327.2M

Earnings Y/Y

-24.53%

Earnings Q/Q

-11.22%

Price Action

52 Week Range

7.2527.40

(Low)(High)

Last 7 days

-17.5%

Last 30 days

-43.6%

Last 90 days

-53.2%

Trailing 12 Months

-62.8%

ARQT Financial Health

Current Ratio

11.57

Debt/Equity

0.94

Debt/Cashflow

-1.31

ARQT Investor Care

Shares Dilution (1Y)

19.47%

Diluted EPS (TTM)

-5.65

Peers (Alternatives to Arcutis Biotherapeutics)

View All Peers In Detail

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
AMGN	116.8B	26.2B	-8.85%	-12.37%	14.75	4.46	-0.48%	38.34%
GILD	95.3B	27.0B	-7.15%	22.78%	17.06	3.52	-1.56%	23.65%
MRNA	49.5B	15.1B	-3.01%	-12.71%	10.35	3.29	-33.37%	-67.32%
BIIB	43.1B	10.1B	-1.82%	44.85%	13.78	4.27	-6.61%	115.98%
MID-CAP
NBIX	8.8B	1.6B	-10.82%	-3.21%	137.28	5.5	32.38%	-10.36%
DNLI	4.0B	-	17.83%	16.01%	-10.8	36.9	122.90%	-29.67%
BEAM	2.4B	76.7M	3.87%	-11.56%	-7.51	30.96	41.73%	-32.75%
BBIO	2.2B	107.9M	-6.75%	87.02%	-4.48	20.12	54.84%	17.36%
SMALL-CAP
RCUS	1.5B	119.0M	13.50%	5.58%	-5.31	12.45	-69.61%	-584.39%
REPL	1.1B	10.0M	10.82%	23.60%	-6.03	105.01	215.65%	-47.65%
NVAX	641.1M	-	-3.13%	-86.56%	-0.55	0.32	72.89%	12.32%
FATE	487.0M	136.9M	-18.29%	-78.97%	-2.07	3.56	116.83%	-0.93%
SGMO	191.0M	241.0M	-22.11%	-68.89%	-1.5	0.79	113.96%	27.87%
VXRT	166.8M	697.0K	51.20%	-67.02%	-1.55	239.29	47.98%	-35.48%
IBIO	9.0M	-	-32.41%	-88.55%	-0.12	3.21	0.51%	-129.47%

Financials for Arcutis Biotherapeutics

Income Statement (Last 12 Months)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q1
Revenue	133.9%	8,622,667	3,686,000			-
Operating Expenses	5.4%	321,731,000	305,313,000	305,214,000	233,072,000	-
S&GA Expenses	17.6%	122,124,000	103,829,000	68,523,000	-	-
R&D Expenses	-2.9%	177,158,000	182,435,000	201,116,000	164,549,000	-
Interest Expenses	33.2%	20,856,000	15,652,000	8,737,000	1,838,000	-
Net Income	-5.1%	-327,234,000	-311,458,000	-310,765,000	-234,638,000	-
Net Income Margin	21.1%	-84.50	-107	-	-	-
Free Cahsflow	-8.0%	-258,048,000	-238,830,000	-185,964,000	-	-

Balance Sheet					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Assets	-15.5%	379	449	509	300	364
Current Assets	-15.9%	368	437	497	295	359
Cash Equivalents	53.5%	82.00	54.00	82.00	62.00	70.00
Inventory	13.8%	9.00	8.00	4.00	-	-
Net PPE	10.0%	2.00	2.00	2.00	2.00	2.00
Liabilities	0.0%	240	240	238	105	110
Current Liabilities	-2.1%	37.00	38.00	37.00	27.00	33.00
Long Term Debt	169.0%	197	73.00	73.00	-	-
LT Debt, Non Current	0.5%	199	198	197	73.00	73.00
Shareholder's Equity	-33.3%	140	210	271	195	254
Retained Earnings	-11.1%	-799	-719	-647	-540	-472
Additional Paid-In Capital	1.0%	940	930	920	737	727
Accumulated Depreciation	18.8%	1.00	1.00	1.00	-	-
Shares Outstanding	0.5%	61.00	61.00	61.00	52.00	51.00

Cashflow (Last 12 Months)					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Cashflow From Operations	-9.1%	-281	-257	-238	-211	-185
Share Based Compensation	9.0%	36.00	33.00	29.00	26.00	22.00
Cashflow From Investing	106.0%	5.00	-87.20	-105	95.00	-122
Cashflow From Financing	-4.8%	287	302	374	89.00	89.00

Risks for ARQT

What is the probability of a big loss on ARQT?

94.9%

Probability that Arcutis Biotherapeutics stock will be more than 20% underwater in next one year

81.7%

Probability that Arcutis Biotherapeutics stock will be more than 30% underwater in next one year.

68%

Probability that Arcutis Biotherapeutics stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ARQT drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Arcutis Biotherapeutics was unfortunately bought at previous high price.

Drawdowns

Returns for ARQT

Cumulative Returns on ARQT

-38.5%

3-Year Cumulative Returns

Which funds bought or sold ARQT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-05-26	ProShare Advisors LLC	sold off	-100	-153,609	-	-%
2023-05-22	AMERIPRISE FINANCIAL INC	added	5.05	-2,639,930	9,402,070	-%
2023-05-18	NEW YORK STATE COMMON RETIREMENT FUND	reduced	-19.98	-179,000	264,000	-%
2023-05-18	JPMORGAN CHASE & CO	added	23.38	-55,000	605,000	-%
2023-05-17	Thrivent Financial for Lutherans	unchanged	-	-129,000	373,000	-%
2023-05-17	Advisory Services Network, LLC	unchanged	-	-1,653	4,785	-%
2023-05-16	JANE STREET GROUP, LLC	new	-	288,805	288,805	-%
2023-05-16	SUSQUEHANNA INTERNATIONAL GROUP, LLP	added	376	839,824	1,169,890	-%
2023-05-16	SRS Capital Advisors, Inc.	added	23.53	-41.00	462	-%
2023-05-15	Balyasny Asset Management L.P.	new	-	487,168	487,168	-%

Latest Funds Activity

Are funds buying ARQT calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own ARQT

No. of Funds

Arcutis Biotherapeutics News

Schedule 13G FIlings of Arcutis Biotherapeutics

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2023	point72 asset management, l.p.	1.8%	1,103,576	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 08, 2023	state street corp	6.04%	3,679,385	SC 13G
Feb 03, 2023	blackrock inc.	8.6%	5,214,258	SC 13G/A
Aug 26, 2022	orbimed advisors llc	4.7%	2,828,356	SC 13D/A
Jun 28, 2022	orbimed advisors llc	6.9%	3,534,537	SC 13D/A
May 27, 2022	bain capital life sciences fund, l.p.	5.3%	2,721,436	SC 13D/A
Apr 08, 2022	orbimed advisors llc	7.6%	3,840,564	SC 13D/A
Feb 14, 2022	point72 asset management, l.p.	5.3%	2,644,177	SC 13G/A
Feb 09, 2022	fmr llc	-	0	SC 13G/A

ARQT Fair Value

Show Fair-Value

Recent SEC filings of Arcutis Biotherapeutics

View All Filings

Date Filed	Form Type	Document
May 24, 2023	8-K	Current Report
May 09, 2023	10-Q	Quarterly Report
May 09, 2023	8-K	Current Report
Apr 18, 2023	4	Insider Trading
Apr 18, 2023	DEF 14A	DEF 14A
Apr 18, 2023	DEFA14A	DEFA14A
Apr 17, 2023	144	Notice of Insider Sale Intent
Apr 10, 2023	4	Insider Trading
Mar 31, 2023	4/A	Insider Trading
Mar 08, 2023	4	Insider Trading

Latest Insider Trading transactions for ARQT

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-04-17	Welgus Howard G.	sold	-118,728	13.968	-8,500	-
2023-04-17	Welgus Howard G.	acquired	14,285	1.6806	8,500	-
2023-04-06	Welgus Howard G.	acquired	14,285	1.6806	8,500	-
2023-04-06	Welgus Howard G.	sold	-102,085	12.01	-8,500	-
2023-03-06	Watanabe Todd Franklin	sold	-37,167	15.2638	-2,435	see remarks
2023-03-06	Burrows Scott L	sold	-4,441	15.2634	-291	chief financial officer
2023-03-06	OSBORNE DAVID W	sold	-10,531	15.2634	-690	chief technical officer
2023-03-06	Burnett Patrick	sold	-12,989	15.2634	-851	see remarks
2023-03-06	Lock Kenneth A.	sold	-12,684	15.2636	-831	chief commercial officer
2023-03-06	Turney Patricia A.	sold	-12,684	15.2635	-831	svp, operations

About Arcutis Biotherapeutics

Todd F. Watanabe

www.arcutis.com

150

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

ARQT Income Statement

2023-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenues:
Revenue, Product and Service [Extensible Enumeration]	Product [Member]	Product [Member]
Total revenues	$ 2,781	$ 0
Operating expenses:
Cost of sales	783	0
Research and development	35,345	40,622
Selling, general, and administrative	42,918	22,006
Total operating expenses	79,046	62,628
Loss from operations	(76,265)	(62,628)
Other income (expense):
Other income, net	3,207	142
Interest expense	(7,042)	(1,838)
Total other income (expense)	(3,835)	(1,696)
Other comprehensive income (loss):
Unrealized income (loss) on marketable securities	724	(765)
Foreign currency translation adjustment	(52)	0
Total other comprehensive income (loss)	672	(765)
Net loss	(80,100)	(64,324)
Comprehensive loss	$ (79,428)	$ (65,089)
Per share information:
Net loss per share, basic (in USD per share)	$ (1.31)	$ (1.27)
Net loss per share, diluted (in USD per share)	$ (1.31)	$ (1.27)
Weighted-average shares used in computing net loss per share, basic (in shares)	61,169,089	50,513,524
Weighted-average shares used in computing net loss per share, diluted (in shares)	61,169,089	50,513,524

ARQT Balance Sheet

2023-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 81,405	$ 53,641
Restricted cash	925	1,234
Trade receivables, net	12,769	8,458
Marketable securities	251,000	355,948
Inventories	8,551	7,514
Prepaid expenses and other current assets	13,026	10,611
Total current assets	367,676	437,406
Property, plant, and equipment, net	2,070	1,881
Intangible assets, net	7,000	7,188
Operating lease right-of-use asset	2,634	2,721
Other assets	78	78
Total assets	379,458	449,274
Current liabilities:
Accounts payable	12,485	8,827
Accrued liabilities	23,864	28,323
Operating lease liability	676	657
Total current liabilities	37,025	37,807
Operating lease liability, noncurrent	3,938	4,117
Long-term debt, net	198,763	197,769
Total liabilities	239,726	239,693
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March 31, 2023 and December 31, 2022; no shares issued and outstanding at March 31, 2023 and December 31, 2022;	0	0
Common stock, $0.0001 par value; 300,000,000 shares authorized at March 31, 2023 and December 31, 2022; 61,369,061 and 61,052,250 shares issued at March 31, 2023 and December 31, 2022, respectively; 61,357,932 and 61,037,403 shares outstanding at March 31, 2023 and December 31, 2022, respectively	6	6
Additional paid-in capital	940,004	930,425
Accumulated other comprehensive loss	(414)	(1,086)
Accumulated deficit	(799,864)	(719,764)
Total stockholders’ equity	139,732	209,581
Total liabilities and stockholders’ equity	$ 379,458	$ 449,274